[article]
Titre : |
Personalized at-home neurofeedback compared to long-acting methylphenidate in children with ADHD: NEWROFEED, a European randomized noninferiority trial |
Type de document : |
Texte imprimé et/ou numérique |
Auteurs : |
D. PURPER-OUAKIL, Auteur ; H. BLASCO-FONTECILLA, Auteur ; T. ROS, Auteur ; Eric ACQUAVIVA, Auteur ; Tobias BANASCHEWSKI, Auteur ; Sarah BAUMEISTER, Auteur ; E. BOUSQUET, Auteur ; A. BUSSALB, Auteur ; M. DELHAYE, Auteur ; R. DELORME, Auteur ; R. DRECHSLER, Auteur ; A. GOUJON, Auteur ; A. HÄGE, Auteur ; A. KAISER, Auteur ; L. MAYAUD, Auteur ; K. MECHLER, Auteur ; C. MENACHE, Auteur ; O. REVOL, Auteur ; F. TAGWERKER, Auteur ; S. WALITZA, Auteur ; A. M. WERLING, Auteur ; Stéphanie BIOULAC, Auteur ; Daniel BRANDEIS, Auteur |
Article en page(s) : |
p.187-198 |
Langues : |
Anglais (eng) |
Mots-clés : |
Attention-deficit hyperactivity disorder methylphenidate neurofeedback randomized clinical trial |
Index. décimale : |
PER Périodiques |
Résumé : |
BACKGROUND: Neurofeedback is considered a promising intervention for the treatment of attention-deficit hyperactivity disorder (ADHD). NEWROFEED is a prospective, multicentre, randomized (3:2), reference drug-controlled trial in children with ADHD aged between 7 and 13?years. The main objective of NEWROFEED was to demonstrate the noninferiority of personalized at-home neurofeedback (NF) training versus methylphenidate in the treatment of children with ADHD. METHODS: The NF group (n?=?111) underwent eight visits and two treatment phases of 16 to 20 at-home sessions with down-training of the theta/beta ratio (TBR) for children with high TBR and enhancing the sensorimotor rhythm (SMR) for the others. The control group (n?=?67) received optimally titrated long-acting methylphenidate. The primary endpoint was the change between baseline and endpoint in the Clinician ADHD-RS-IV total score in the per-protocol population (90 NF/59 controls). TRIAL REGISTRATION: US National Institute of Health, ClinicalTrials.gov #NCT02778360. RESULTS: Our study failed to demonstrate noninferiority of NF versus methylphenidate (mean between-group difference 8.09 90% CI [8.09; 10.56]). However, both treatment groups showed significant pre-post improvements in core ADHD symptoms and in a broader range of problems. Reduction in the Clinician ADHD-RS-IV total score between baseline and final visit (D90) was 26.7% (SMD?=?0.89) in the NF and 46.9% (SMD?=?2.03) in the control group. NF effects increased whereas those of methylphenidate were stable between intermediate and final visit. CONCLUSIONS: Based on clinicians' reports, the effects of at-home NF were inferior to those of methylphenidate as a stand-alone treatment. |
En ligne : |
http://dx.doi.org/10.1111/jcpp.13462 |
Permalink : |
https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=457 |
in Journal of Child Psychology and Psychiatry > 63-2 (February 2022) . - p.187-198
[article] Personalized at-home neurofeedback compared to long-acting methylphenidate in children with ADHD: NEWROFEED, a European randomized noninferiority trial [Texte imprimé et/ou numérique] / D. PURPER-OUAKIL, Auteur ; H. BLASCO-FONTECILLA, Auteur ; T. ROS, Auteur ; Eric ACQUAVIVA, Auteur ; Tobias BANASCHEWSKI, Auteur ; Sarah BAUMEISTER, Auteur ; E. BOUSQUET, Auteur ; A. BUSSALB, Auteur ; M. DELHAYE, Auteur ; R. DELORME, Auteur ; R. DRECHSLER, Auteur ; A. GOUJON, Auteur ; A. HÄGE, Auteur ; A. KAISER, Auteur ; L. MAYAUD, Auteur ; K. MECHLER, Auteur ; C. MENACHE, Auteur ; O. REVOL, Auteur ; F. TAGWERKER, Auteur ; S. WALITZA, Auteur ; A. M. WERLING, Auteur ; Stéphanie BIOULAC, Auteur ; Daniel BRANDEIS, Auteur . - p.187-198. Langues : Anglais ( eng) in Journal of Child Psychology and Psychiatry > 63-2 (February 2022) . - p.187-198
Mots-clés : |
Attention-deficit hyperactivity disorder methylphenidate neurofeedback randomized clinical trial |
Index. décimale : |
PER Périodiques |
Résumé : |
BACKGROUND: Neurofeedback is considered a promising intervention for the treatment of attention-deficit hyperactivity disorder (ADHD). NEWROFEED is a prospective, multicentre, randomized (3:2), reference drug-controlled trial in children with ADHD aged between 7 and 13?years. The main objective of NEWROFEED was to demonstrate the noninferiority of personalized at-home neurofeedback (NF) training versus methylphenidate in the treatment of children with ADHD. METHODS: The NF group (n?=?111) underwent eight visits and two treatment phases of 16 to 20 at-home sessions with down-training of the theta/beta ratio (TBR) for children with high TBR and enhancing the sensorimotor rhythm (SMR) for the others. The control group (n?=?67) received optimally titrated long-acting methylphenidate. The primary endpoint was the change between baseline and endpoint in the Clinician ADHD-RS-IV total score in the per-protocol population (90 NF/59 controls). TRIAL REGISTRATION: US National Institute of Health, ClinicalTrials.gov #NCT02778360. RESULTS: Our study failed to demonstrate noninferiority of NF versus methylphenidate (mean between-group difference 8.09 90% CI [8.09; 10.56]). However, both treatment groups showed significant pre-post improvements in core ADHD symptoms and in a broader range of problems. Reduction in the Clinician ADHD-RS-IV total score between baseline and final visit (D90) was 26.7% (SMD?=?0.89) in the NF and 46.9% (SMD?=?2.03) in the control group. NF effects increased whereas those of methylphenidate were stable between intermediate and final visit. CONCLUSIONS: Based on clinicians' reports, the effects of at-home NF were inferior to those of methylphenidate as a stand-alone treatment. |
En ligne : |
http://dx.doi.org/10.1111/jcpp.13462 |
Permalink : |
https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=457 |
|